PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3029% below fair value
$16.24+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $2.25BP/E –Yield 7.14%
Perrigo ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Perrigo's ebitda for the twelve months ending Sep 26, 2026 was -$1.27B, down 307.2% year over year. For fiscal 2025 it was -$784.70M, down 278.8% from the year before. The highest annual figure on record is $1.04B in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$784.70M | -278.8% |
| FY2024 | Dec 31, 2024 | $438.80M | -14.2% |
| FY2023 | Dec 31, 2023 | $511.40M | +22.5% |
| FY2022 | Dec 31, 2022 | $417.50M | -42.2% |
| FY2021 | Dec 31, 2021 | $722.60M | +11.2% |
| FY2020 | Dec 31, 2020 | $650.00M | +13.8% |
| FY2019 | Dec 31, 2019 | $571.20M | -13.5% |
| FY2018 | Dec 31, 2018 | $660.10M | -36.7% |
| FY2017 | Dec 31, 2017 | $1.04B | +12.0% |
| FY2015 | Jun 27, 2015 | $931.20M | +19.8% |
| FY2014 | Jun 28, 2014 | $777.50M | -7.4% |
| FY2013 | Jun 29, 2013 | $839.30M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 26, 2026 | $104.90M | -33.6% |
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $119.30M | -9.4% |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | -$289.00M | -327.9% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$1.20B | -717.6% |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $158.00M | -2.9% |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | $131.70M | +137.7% |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | $126.80M | +384.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $194.50M | +176.7% |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | $162.70M | +6.3% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | $55.40M | -63.2% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | $26.20M | -80.9% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $70.30M | -45.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $153.10M | +25.9% |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $150.70M | +96.7% |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | $137.20M | +50.4% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $128.10M | +6.7% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | $121.60M | -76.2% |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | $76.60M | – |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | $91.20M | -35.7% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $120.10M | -12.8% |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | $511.80M | +191.8% |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | -$51.00M | -132.4% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $141.80M | -21.0% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $137.70M | +108.6% |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | $175.40M | +12.1% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $157.40M | +5.0% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $179.50M | -9.8% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $66.00M | -68.1% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $156.40M | – |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $149.90M | -26.2% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $198.90M | -25.2% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $207.10M | -23.4% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | -$15.80M | -105.8% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $203.00M | -22.0% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $265.80M | +11.7% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $270.30M | +288.9% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $274.70M | – |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | $260.20M | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $237.90M | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | $69.50M | – |
See a number that looks wrong?